These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Variability in Action Selection Relates to Striatal Dopamine 2/3 Receptor Availability in Humans: A PET Neuroimaging Study Using Reinforcement Learning and Active Inference Models. Adams RA; Moutoussis M; Nour MM; Dahoun T; Lewis D; Illingworth B; Veronese M; Mathys C; de Boer L; Guitart-Masip M; Friston KJ; Howes OD; Roiser JP Cereb Cortex; 2020 May; 30(6):3573-3589. PubMed ID: 32083297 [TBL] [Abstract][Full Text] [Related]
8. Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. Graff-Guerrero A; Redden L; Abi-Saab W; Katz DA; Houle S; Barsoum P; Bhathena A; Palaparthy R; Saltarelli MD; Kapur S Int J Neuropsychopharmacol; 2010 Apr; 13(3):273-87. PubMed ID: 19751545 [TBL] [Abstract][Full Text] [Related]
9. Syntheses and in vitro evaluation of fluorinated naphthoxazines as dopamine D2/D3 receptor agonists: radiosynthesis, ex vivo biodistribution and autoradiography of [(18)F]F-PHNO. Vasdev N; Seeman P; Garcia A; Stableford WT; Nobrega JN; Houle S; Wilson AA Nucl Med Biol; 2007 Feb; 34(2):195-203. PubMed ID: 17307127 [TBL] [Abstract][Full Text] [Related]
10. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO. Girgis RR; Slifstein M; D'Souza D; Lee Y; Periclou A; Ghahramani P; Laszlovszky I; Durgam S; Adham N; Nabulsi N; Huang Y; Carson RE; Kiss B; Kapás M; Abi-Dargham A; Rakhit A Psychopharmacology (Berl); 2016 Oct; 233(19-20):3503-12. PubMed ID: 27525990 [TBL] [Abstract][Full Text] [Related]
11. In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice. Rabiner EA; Slifstein M; Nobrega J; Plisson C; Huiban M; Raymond R; Diwan M; Wilson AA; McCormick P; Gentile G; Gunn RN; Laruelle MA Synapse; 2009 Sep; 63(9):782-93. PubMed ID: 19489048 [TBL] [Abstract][Full Text] [Related]
15. What is the role of the D3 receptor in addiction? A mini review of PET studies with [(11)C]-(+)-PHNO. Payer D; Balasubramaniam G; Boileau I Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jul; 52():4-8. PubMed ID: 23999545 [TBL] [Abstract][Full Text] [Related]
16. Imaging the D3 dopamine receptor across behavioral and drug addictions: Positron emission tomography studies with [(11)C]-(+)-PHNO. Boileau I; Nakajima S; Payer D Eur Neuropsychopharmacol; 2015 Sep; 25(9):1410-20. PubMed ID: 26141509 [TBL] [Abstract][Full Text] [Related]
17. Occupancy of Dopamine D3 and D2 Receptors by Buspirone: A [11C]-(+)-PHNO PET Study in Humans. Le Foll B; Payer D; Di Ciano P; Guranda M; Nakajima S; Tong J; Mansouri E; Wilson AA; Houle S; Meyer JH; Graff-Guerrero A; Boileau I Neuropsychopharmacology; 2016 Jan; 41(2):529-37. PubMed ID: 26089182 [TBL] [Abstract][Full Text] [Related]